The April RSV, meningococcal, and chikungunya vaccine recommendations from the previous ACIP panel are now official policy.
Compared with flu vaccine recipients, those given the RSV and/or shingles vaccine had 18% to 37% lower odds of receiving a dementia diagnosis in the next 18 months.
ACIP's chair signaled that new work groups will take up 2 new topics: cumulative vaccine doses in children and impacts from established vaccines, including hepatitis B in infants.
Secondary bacterial pneumonia rates were significantly higher in the RSV group.
The group is expected to vote on thimerosal, despite no evidence of harm, and will discuss the MMRV use in young children.
The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease.
The approval is the second for an RSV monoclonal antibody preventive for infants.
Estimates varied from 2008 through 2018, with RSV-associated antibiotic prescribing exceeding 10% in peak RSV years and flu-associated prescribing exceeding 20% in peak flu years.
A retrospective analysis of hospitalized VA patients finds that prior flu or RSV infection more than doubled the odds of subsequent Streptococcus pneumoniae infection.
The WHO is recommending use of a maternal RSV vaccine and the monoclonal antibody nirsevimab to protect infants against the virus.
